4mmt: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Crystal Structure of Prefusion-stabilized RSV F Variant DS-Cav1 at pH 9.5== | |||
<StructureSection load='4mmt' size='340' side='right' caption='[[4mmt]], [[Resolution|resolution]] 3.05Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4mmt]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Bpt4 Bpt4] and [http://en.wikipedia.org/wiki/Hrsva Hrsva]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4MMT OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4MMT FirstGlance]. <br> | |||
</td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4jhw|4jhw]], [[4mmq|4mmq]], [[4mmr|4mmr]], [[4mms|4mms]], [[4mmu|4mmu]], [[4mmv|4mmv]]</td></tr> | |||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">F ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11259 HRSVA]), F ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=10665 BPT4])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4mmt FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4mmt OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4mmt RCSB], [http://www.ebi.ac.uk/pdbsum/4mmt PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Respiratory syncytial virus (RSV) is the leading cause of hospitalization for children under 5 years of age. We sought to engineer a viral antigen that provides greater protection than currently available vaccines and focused on antigenic site O, a metastable site specific to the prefusion state of the RSV fusion (F) glycoprotein, as this site is targeted by extremely potent RSV-neutralizing antibodies. Structure-based design yielded stabilized versions of RSV F that maintained antigenic site O when exposed to extremes of pH, osmolality, and temperature. Six RSV F crystal structures provided atomic-level data on how introduced cysteine residues and filled hydrophobic cavities improved stability. Immunization with site O-stabilized variants of RSV F in mice and macaques elicited levels of RSV-specific neutralizing activity many times the protective threshold. | |||
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus.,McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD Science. 2013 Nov 1;342(6158):592-8. doi: 10.1126/science.1243283. PMID:24179220<ref>PMID:24179220</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== References == | |||
== | <references/> | ||
__TOC__ | |||
[[Category: Graham, B S | </StructureSection> | ||
[[Category: Joyce, M G | [[Category: Bpt4]] | ||
[[Category: Kwong, P D | [[Category: Hrsva]] | ||
[[Category: Mclellan, J S | [[Category: Graham, B S]] | ||
[[Category: Sastry, M | [[Category: Joyce, M G]] | ||
[[Category: Stewart-Jones, G B.E | [[Category: Kwong, P D]] | ||
[[Category: Yang, Y | [[Category: Mclellan, J S]] | ||
[[Category: Sastry, M]] | |||
[[Category: Stewart-Jones, G B.E]] | |||
[[Category: Yang, Y]] | |||
[[Category: Fusion]] | [[Category: Fusion]] | ||
[[Category: Membrane]] | [[Category: Membrane]] | ||
[[Category: Structure-based vaccine design]] | [[Category: Structure-based vaccine design]] | ||
[[Category: Viral protein]] | [[Category: Viral protein]] |